Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent BioSolutions	$6.35 -1.8%	$5.31	$4.02 ▼ $15.10	$344.39M	2.09	1.85 million shs	901,777 shs
IRWD Ironwood Pharmaceuticals	$0.60 -4.4%	$0.91	$0.53 ▼ $7.11	$97.64M	0.37	2.59 million shs	4.33 million shs
MYGN Myriad Genetics	$4.18 +0.5%	$6.69	$3.81 ▼ $29.30	$385.30M	2.01	1.17 million shs	2.42 million shs
RIGL Rigel Pharmaceuticals	$19.30 -1.2%	$18.34	$7.48 ▼ $29.82	$344.93M	1.34	217,836 shs	230,423 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent BioSolutions	-0.48%	-0.08%	+18.41%	-13.28%	+39.33%
IRWD Ironwood Pharmaceuticals	+6.60%	+1.84%	-32.83%	-60.78%	-89.53%
MYGN Myriad Genetics	-3.93%	+5.85%	-42.22%	-61.23%	-81.67%
RIGL Rigel Pharmaceuticals	+1.77%	-1.01%	-0.20%	-15.31%	+112.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent BioSolutions	4.3409 of 5 stars	3.5	1.0	4.6	3.5	2.5	1.3
IRWD Ironwood Pharmaceuticals	4.6153 of 5 stars	4.1	3.0	3.4	3.7	0.8	1.9
MYGN Myriad Genetics	3.9178 of 5 stars	4.0	1.0	4.1	1.8	1.7	0.6
RIGL Rigel Pharmaceuticals	2.5247 of 5 stars	3.2	1.0	0.0	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent BioSolutions	3.00	Buy	$14.33	125.90% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	692.73% Upside
MYGN Myriad Genetics	2.06	Hold	$14.79	253.73% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	88.60% Upside

Current Analyst Ratings Breakdown

Latest IRWD, MYGN, EBS, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00
5/7/2025	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$22.00 ➝ $6.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
4/17/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent BioSolutions	$930.30M	0.37	$0.71 per share	8.92	$12.51 per share	0.51
IRWD Ironwood Pharmaceuticals	$317.68M	0.31	N/A	N/A	($2.21) per share	-0.27
MYGN Myriad Genetics	$831.30M	0.46	N/A	N/A	$9.53 per share	0.44
RIGL Rigel Pharmaceuticals	$203.08M	1.70	N/A	N/A	($1.64) per share	-11.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent BioSolutions	-$760.50M	-$2.71	N/A	3.07	N/A	-18.55%	-9.91%	-3.31%	8/5/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	-$1.00B	-$0.20	N/A	2.41	N/A	-0.65%	-0.96%	0.74%	8/14/2025 (Estimated)
MYGN Myriad Genetics	-$263.30M	-$1.12	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	8/5/2025 (Estimated)
RIGL Rigel Pharmaceuticals	-$25.09M	$2.07	137.87	18.38	N/A	2.46%	-14.80%	3.03%	8/5/2025 (Estimated)

Latest IRWD, MYGN, EBS, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	EBS Emergent BioSolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million
3/4/2025	Q4 2024	RIGL Rigel Pharmaceuticals	$0.30	$0.80	+$0.50	$0.80	$57.59 million	$57.60 million
3/3/2025	Q4 2024	EBS Emergent BioSolutions	-$0.35	$0.05	+$0.40	-$0.58	$254.67 million	$194.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent BioSolutions	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent BioSolutions	1.30	2.88	1.47
IRWD Ironwood Pharmaceuticals	N/A	3.62	3.62
MYGN Myriad Genetics	0.05	1.90	1.73
RIGL Rigel Pharmaceuticals	N/A	1.96	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent BioSolutions	78.40%
IRWD Ironwood Pharmaceuticals	N/A
MYGN Myriad Genetics	99.02%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
EBS Emergent BioSolutions	1.20%
IRWD Ironwood Pharmaceuticals	12.90%
MYGN Myriad Genetics	2.40%
RIGL Rigel Pharmaceuticals	9.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent BioSolutions	2,420	54.28 million	53.53 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	139.38 million	Optionable
MYGN Myriad Genetics	2,600	92.18 million	89.12 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.02 million	Optionable

IRWD, MYGN, EBS, and RIGL Headlines

Recent News About These Companies

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?

May 29 at 10:46 AM | zacks.com

Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?

May 28 at 10:56 AM | zacks.com

Rigel to Present at the Jefferies Global Healthcare Conference

May 28 at 8:05 AM | prnewswire.com

Jane Street Group LLC Has $1.05 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

May 24, 2025 | marketbeat.com

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 22, 2025 | prnewswire.com

Soleus Capital Management L.P. Boosts Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

May 21, 2025 | marketbeat.com

17,123 Shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Acquired by Dimensional Fund Advisors LP

May 20, 2025 | marketbeat.com

Ensign Peak Advisors Inc Makes New $1.44 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

May 19, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Raises Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

May 17, 2025 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 16, 2025 | marketbeat.com

Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now

May 14, 2025 | zacks.com

Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?

May 13, 2025 | zacks.com

Upgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Forecasts

May 11, 2025 | finance.yahoo.com

B. Riley Expects Reduced Earnings for Rigel Pharmaceuticals

May 11, 2025 | marketbeat.com

HC Wainwright Has Optimistic Outlook of RIGL Q2 Earnings

May 11, 2025 | marketbeat.com

B. Riley Equities Analysts Lift Earnings Estimates for RIGL

May 10, 2025 | marketbeat.com

Equities Analysts Offer Predictions for RIGL Q3 Earnings

May 10, 2025 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Hold" by Analysts

May 10, 2025 | marketbeat.com

Rigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting Next

May 9, 2025 | uk.finance.yahoo.com

Earnings Estimates Rising for Rigel (RIGL): Will It Gain?

May 9, 2025 | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00

May 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD, MYGN, EBS, and RIGL Company Descriptions

Emergent BioSolutions NYSE:EBS

$6.34 -0.12 (-1.78%)

Closing price 03:59 PM Eastern

Extended Trading

$6.00 -0.34 (-5.36%)

As of 07:26 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.60 -0.03 (-4.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.64 +0.04 (+6.23%)

As of 07:27 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Myriad Genetics NASDAQ:MYGN

$4.18 +0.02 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$4.24 +0.07 (+1.56%)

As of 06:18 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Rigel Pharmaceuticals NASDAQ:RIGL

$19.30 -0.23 (-1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$19.18 -0.12 (-0.62%)

As of 05:20 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time